Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Summary of clinical presentation

Published bySilvester Peters Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Summary of clinical presentation"— Presentation transcript:

1 Figure 1 Summary of clinical presentation
Summary of clinical presentation (A) Head CT on days 1 and 2 showed extensive vasogenic edema in the right temporal-parietal region, a focal hypodensity in the right frontal region associated with mass effect, and subfalcine herniation to the left with early central downward herniation. Therefore, an urgent right-sided craniectomy was performed to relieve the pressure and obtain a biopsy of the right frontal region. (B) Chest x-ray on day 2 showed patchy congestion consistent with a right lower lobe pneumonia as well as pulmonary edema. Later, autopsy results at day 5 confirmed these findings and also showed mucoid purulent secretions in the bronchial tree. Myocarditis was also noted at autopsy with a primary neutrophilic reaction. Nasopharyngeal swab was negative for enteroviruses and respiratory viruses via PCR. Cold agglutinins were positive at a titer of 64 when tested against adult cells at 4°C. Rick Magun et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e187 © 2016 American Academy of Neurology

Download ppt "Figure 1 Summary of clinical presentation"

Similar presentations

Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients by Alpana Waghmare, Steven.

Clinical disease due to enterovirus D68 in adult hematologic malignancy patients and hematopoietic cell transplant recipients by Alpana Waghmare, Steven.
Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.

Figure 2. A patient with multifocal nodular lesions diagnosed with CNS tuberculosis A patient with multifocal nodular lesions diagnosed with CNS tuberculosis.
Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.

Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure Neuroimaging and pathology

Figure Neuroimaging and pathology
Figure 4 Diagram of various known microbes and the present pathogen On the basis of morphologic features, the microbes could be categorized into 5 groups:

Figure 4 Diagram of various known microbes and the present pathogen On the basis of morphologic features, the microbes could be categorized into 5 groups:
Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.

Figure 2. Change in total PSPRS score from baseline to each study visit for all participants Change in total PSPRS score from baseline to each study visit.
Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.

Figure 1 Coronal MRI images showing the evolution of white matter abnormality and atrophy of patient 1 Coronal MRI images showing the evolution of white.
Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.
Figure 1. Prebiopsy and postbiopsy MRI

Figure 1. Prebiopsy and postbiopsy MRI
Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.
Figure Brain MRI and biopsy specimens from the pontine lesion

Figure Brain MRI and biopsy specimens from the pontine lesion
Figure 1 MRI, pathology, and EEG findings(A) Axial fluid-attenuated inversion recovery (FLAIR) MRI sequences of the brain showing right frontal and parietal.

Figure 1 MRI, pathology, and EEG findings(A) Axial fluid-attenuated inversion recovery (FLAIR) MRI sequences of the brain showing right frontal and parietal.
Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.

Figure 2 Neuropathologic examination for lymphoma etiology (patients 1–4)‏ Neuropathologic examination for lymphoma etiology (patients 1–4) Immunohistochemical.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure MRIs and histopathology of the biopsy specimens

Figure MRIs and histopathology of the biopsy specimens
Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer

Figure 2 Correlation between total IgG levels and anti-AQP4 IgG titer
Figure Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes. Four months after symptom onset(A) Two fluorodeoxyglucose.

Figure Four months after symptom onset(A) Two fluorodeoxyglucose positive left inguinal lymph nodes. Four months after symptom onset(A) Two fluorodeoxyglucose.
Figure 2 Binding of the patient's IgG to Purkinje cells is inhibited by pretreatment of rat tissue with anti-VGCC antibodies, confirming specificity of.

Figure 2 Binding of the patient's IgG to Purkinje cells is inhibited by pretreatment of rat tissue with anti-VGCC antibodies, confirming specificity of.
Figure 3 EEG demonstrating ictal seizure discharges in a patient with faciobrachial dystonic seizures The EEG of a 56-year-old woman with faciobrachial.

Figure 3 EEG demonstrating ictal seizure discharges in a patient with faciobrachial dystonic seizures The EEG of a 56-year-old woman with faciobrachial.

Similar presentations

Ads by Google